Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status (PARADIGM‐2). This evidence concerns the gene MGMT and glioblastoma.